Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shahid Rafiq

Neuromusculoskeletal Medicine & OMM Frederick, MD Medical Doctor

NPI 1447214549 CMS profile 338035

196 Thomas Johnson Dr, Suite 120, Frederick, MD 21702

Open in the dashboard

General payments

$16,489

735 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$977,152 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Shahid Rafiq of Frederick, MD is reported in the CMS Open Payments database as having received $16,489 across 735 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $977,152 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,749 95
2024 General $1,798 90
2023 General $1,694 97
2022 General $3,908 109
2021 General $2,031 122
2020 General $1,427 88
2019 General $3,882 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shahid Rafiq
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Shahid Rafiq were reported at $1,749. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Shahid Rafiq Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $3,882 $92 $27–$283 $163
2020 $1,427 $85 $20–$411 $114
2021 $2,031 $120 $32–$548 $132
2022 $3,908 $96 $32–$518 $149
2023 $1,694 $92 $33–$328 $160
2024 $1,798 $122 $35–$378 $164
2025 $1,749 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,727 130 payments
  2. Brainsway USA Inc $1,928 1 payment
  3. AbbVie, Inc. $1,741 119 payments
  4. Allergan Inc. $648 53 payments
  5. Teva Pharmaceuticals USA, Inc. $556 27 payments
  6. UCB, Inc. $542 17 payments
  7. Supernus Pharmaceuticals, Inc. $528 29 payments
  8. Amgen Inc. $521 30 payments
  9. Genentech USA, Inc. $415 11 payments
  10. Lilly USA, LLC $380 21 payments
  11. Other $6,502 297 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,022 727 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,973 4 payments
  3. Gift $1,430 3 payments
  4. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. BrainsWay Deep TMS $1,928 1 payment
  2. GILENYA $1,554 12 payments
  3. UBRELVY $1,259 88 payments
  4. QULIPTA $750 51 payments
  5. AIMOVIG $643 40 payments
  6. KESIMPTA $578 66 payments
  7. TROKENDI XR $486 26 payments
  8. MAYZENT $474 44 payments
  9. BOTOX $430 36 payments
  10. Briviact $385 12 payments
  11. Other $9,272 488 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

2,731

Median for Neurology: 833

Drug cost

$360,428

Median for Neurology: $202,670

Branded share of claims

12.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aubagio Teriflunomide Brand 12 $112,710
Ubrelvy Ubrogepant Brand 31 $42,656
Nurtec Odt Rimegepant Sulfate Brand 22 $41,859
Qulipta Atogepant Brand 14 $24,280
Emgality Pen Galcanezumab-Gnlm Brand 28 $24,278
Eliquis Apixaban Brand 21 $21,180
Fycompa Perampanel Brand 12 $14,258
Aimovig Autoinjector Erenumab-Aooe Brand 18 $13,085
Memantine Hcl Generic 209 $10,242
Rivastigmine Generic 33 $6,896

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$487,481

Of which drugs: $62,038

Medicare patients

1,592

Average age 74

Services billed

15,705

915 women, 677 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 39%
Ischemic heart disease 38%
Depression 38%
Alzheimer's or dementia 30%
Chronic kidney disease 24%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 11,800 $58,731

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $172
$172 — —
UBRELVY
  • AbbVie, Inc. $139
$139 31 —
QULIPTA
  • AbbVie, Inc. $125
$125 14 —
KISUNLA
  • Lilly USA, LLC $98
$98 — —
Gocovri
  • US WorldMeds, LLC $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

735 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record